Article
Exploratory analysis of immunochemotherapy compared to chemotherapy after EGFR-TKI in non-small cell lung cancer patients with EGFR mutation: A multicenter retrospective study.
Thoracic cancer - 1 Apr 2023
Hata Tae, Sakaguchi Chikara, Hirano Keita, Kobe Hiroshi, Ishida Masaki, Nakano Takayuki, Tachibana Yusuke, Tamiya Nobuyo, Shiotsu Shinsuke, Takeda Takayuki, Yamada Tadaaki, Yokoyama Toshihide, Tsuchiya Michiko, Nagasaka Yukio
Abstract excerpt
BACKGROUND: Patients with epidermal growth factor receptor (EGFR)-mutated, advanced non-small cell lung cancer have received immunochemotherapy as one of the treatment options after tyrosine kinase inhibitor (TKI) failure. METHODS: We retrospectively examined EGFR-mutant patients treated with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) therapy or platinum-based chemotherapy (Chemo) after EGFR-TKI...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.